Evidence map›Paper›PMID 28659884›Full record

ArticleFrontiers in microbiology2017

Fungal Glucosylceramide-Specific Camelid Single Domain Antibodies Are Characterized by Broad Spectrum Antifungal Activity.

Barbara De Coninck, Peter Verheesen, Christine M Vos, Inge Van Daele, Miguel F De Bolle, Joao V Vieira, Marnix Peferoen, Bruno P A Cammue, Karin Thevissen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. The antimicrobial activity of ETD151 defensin is dictated by the presence of glycosphingolipids in the targeted organisms.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Membrane-Interacting Antifungal Peptides.Frontiers in cell and developmental biology · 2021
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Barbara De ConinckCentre of Microbial and Plant Genetics, KU LeuvenLeuven, Belgium.
Peter VerheesenAgrosavfe NVGhent, Belgium.
Christine M VosCentre of Microbial and Plant Genetics, KU LeuvenLeuven, Belgium.
Inge Van DaeleAgrosavfe NVGhent, Belgium.
Miguel F De BolleAgrosavfe NVGhent, Belgium.
Joao V VieiraAgrosavfe NVGhent, Belgium.
Marnix PeferoenAgrosavfe NVGhent, Belgium.
Bruno P A CammueCentre of Microbial and Plant Genetics, KU LeuvenLeuven, Belgium.
Karin ThevissenCentre of Microbial and Plant Genetics, KU LeuvenLeuven, Belgium.
KU Leuven · BEVIB-UGent Center for Plant Systems Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemical crop protection is widely used to control plant diseases. However, the adverse effects of pesticide use on human health and environment, resistance development and the impact of regulatory requirements on the crop protection market urges the agrochemical industry to explore innovative and alternative approaches. In that context, we demonstrate here the potential of camelid single domain antibodies (VHHs) generated against fungal glucosylceramides (fGlcCer), important pathogenicity factors. To this end, llamas were immunized with purified fGlcCer and a mixture of mycelium and spores of the fungus

Indexed as

antifungal activityBotrytis cinereacamelid antibodiescrop protectionfungal glucosylceramideVHH

Identifiers

PMID28659884
PMCPMC5469901
OpenAlexW2624684072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.